Immunohistochemical Analysis of the Expression of Breast Markers in Basal-like Breast Carcinomas Defined as Triple Negative Cancers Expressing Keratin 5

被引:10
作者
Zombori, Tamas [1 ]
Cserni, Gabor [1 ,2 ]
机构
[1] Univ Szeged, Dept Pathol, Fac Med, Allomas U 1, H-6725 Szeged, Hungary
[2] Bacs Kiskun Cty Teaching Hosp, Dept Pathol, Kecskemet, Hungary
关键词
Basal-like; Triple negative breast cancer; GATA-3; Mammaglobin; GCDFP-15; NY-BR-1; DISEASE FLUID PROTEIN-15; DIFFERENTIATION ANTIGEN NY-BR-1; UTEROGLOBIN GENE FAMILY; FEMALE GENITAL-TRACT; GATA3; IMMUNOHISTOCHEMISTRY; ESTROGEN-RECEPTOR; CLINICOPATHOLOGICAL ANALYSIS; MAMMAGLOBIN EXPRESSION; DIAGNOSTIC UTILITY; IDENTIFICATION;
D O I
10.1007/s12253-017-0246-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Estrogen and progesterone receptors are possible markers for suggesting a mammary origin of metastatic carcinoma, but are useless in cases of triple negative breast cancers (TNBC). Five other potential markers of breast origin were investigated on tissue microarrays in a series of TNBCs showing keratin 5 expression, consistent with a basal-like phenotype. GATA-3 staining was observed in 82 of 115 triple negative cases (71.3%) including 23 cases with > 5% staining. Mammaglobin staining was detected in 30 cases (26.0%) including 12 with > 5% staining. GCDFP-15 was seen in 23 cases (20.0%) including 9 with > 5% staining. NY-BR-1 positivity was present in 7 cases (6.0%) including 3 patients with > 5% staining. BCA-225 staining was observed in 74 cases (64.3%); however this latter marker lacks also specificity owing to the reported widespread staining in other malignancies. GATA-3, mammaglobin and GCDFP-15 coexpression was seen in one case (0.9%), whereas GATA-3 and mammaglobin or mammaglobin and GCDFP-15 coexpression was present in 2 and 2 cases (1.7%), respectively. Using at least 5% staining as cut-off, the expression of any of the last 4 markers was 34.7%. The expression of GATA-3, mammaglobin, GCDFP-15 and NY-BR-1 is lower in TNBC-s than in breast carcinomas in general, and this may be even lower in basal-like carcinomas. Although these markers are not fully specific, by using them, a subset of basal-like TNBC-s can be identified as of mammary origin. However, a substantial proportion will not show any staining with any of these markers.
引用
收藏
页码:259 / 267
页数:9
相关论文
共 50 条
  • [41] Clinical significance of basal-like subtype in triple-negative breast cancer
    Yutaka Yamamoto
    Mutsuko Ibusuki
    Masahiro Nakano
    Teru Kawasoe
    Ryousuke Hiki
    Hirotaka Iwase
    Breast Cancer, 2009, 16 : 260 - 267
  • [42] A clinically relevant gene signature in triple negative and basal-like breast cancer
    Achim Rody
    Thomas Karn
    Cornelia Liedtke
    Lajos Pusztai
    Eugen Ruckhaeberle
    Lars Hanker
    Regine Gaetje
    Christine Solbach
    Andre Ahr
    Dirk Metzler
    Marcus Schmidt
    Volkmar Müller
    Uwe Holtrich
    Manfred Kaufmann
    Breast Cancer Research, 13
  • [43] Comparative proteomic and clinicopathological analysis of breast adenoid cystic carcinoma and basal-like triple-negative breast cancer
    Yao, Qian
    Hou, Wei
    Chen, Junbing
    Bai, Yanhua
    Long, Mengping
    Huang, Xiaozheng
    Zhao, Chen
    Zhou, Lixin
    Niu, Dongfeng
    FRONTIERS IN MEDICINE, 2022, 9
  • [44] VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer
    Angeles Castilla, Maria
    Angeles Lopez-Garcia, Maria
    Reina Atienza, Maria
    Manuel Rosa-Rosa, Juan
    Diaz-Martin, Juan
    Luisa Pecero, Maria
    Vieites, Begona
    Romero-Perez, Laura
    Benitez, Javier
    Calcabrini, Annarica
    Palacios, Jose
    ENDOCRINE-RELATED CANCER, 2014, 21 (04) : 587 - 599
  • [45] BASAL-LIKE BREAST CANCERS: CLINICOPATHOLOGICAL FEATURES AND OUTCOME
    De Brot, Marina
    Soares, Fernando Augusto
    Agata Stiepcich, Monica Maria
    Curcio, Vinicius S.
    Gobbi, Helenice
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2009, 55 (05): : 529 - 534
  • [46] Basal-like immunophenotype markers and prognosis in early breast cancer
    Cassol, Lina
    Graudenz, Marcia Silveira
    Zelmanowicz, Alice
    Cancela, Anna
    Werutsky, Gustavo
    Rovere, Rodrigo Kraft
    Garicochea, Bernardo
    TUMORI JOURNAL, 2010, 96 (06): : 966 - 970
  • [47] Clinical and pathologic aspects of basal-like breast cancers
    Fadare, Oluwole
    Tavassoli, Fattaneh A.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (03): : 149 - 159
  • [48] Do 'basal-like' breast cancers really exist?
    Gusterson, Barry
    NATURE REVIEWS CANCER, 2009, 9 (02) : 128 - 134
  • [49] BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy
    Bouchalova, Katerina
    Svoboda, Marek
    Kharaishvili, Gvantsa
    Vrbkova, Jana
    Bouchal, Jan
    Trojanec, Radek
    Koudelakova, Vladimira
    Radova, Lenka
    Cwiertka, Karel
    Hajduch, Marian
    Kolar, Zdenek
    TUMOR BIOLOGY, 2015, 36 (06) : 4243 - 4252
  • [50] miRNA-135b Contributes to Triple Negative Breast Cancer Molecular Heterogeneity: Different Expression Profile in Basal-like Versus non-Basal-like Phenotypes
    Uva, Paolo
    Cossu-Rocca, Paolo
    Loi, Federica
    Pira, Giovanna
    Murgia, Luciano
    Orru, Sandra
    Floris, Matteo
    Muroni, Maria Rosaria
    Sanges, Francesca
    Carru, Ciriaco
    Angius, Andrea
    De Miglio, Maria Rosaria
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2018, 15 (06): : 536 - 548